Secobarbital is a barbiturate used for the short-term treatment of insomnia. Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties.
- Mechanism
- Curator reviewed
Secobarbital binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
- Primary indication
- For the Short-term treatment of intractable insomnia for patients habituated to barbituratesCurator reviewed · 2 structured indications
- Formula / weight
- C12H18N2O3 · 238.2829 g/mol (avg)
- First approval
- Canada, 1939 · United States, 1983
- Also known as
- Quinalbarbitone · Secobarbitone
- Brand names
Resolves to
Clinical / RWD
Structure
InChIKey
KQPKPCNLIDLUMF-UHFFFAOYSA-NSMILESCCCC(C)C1(CC=C)C(=O)NC(=O)NC1=OWhat you can answer from here — as of October 02, 2026
11Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Secobarbital, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account